Short answer
Vera Therapeutics, Inc. (VERA) filed an 8-K current report with the SEC on May 26, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Three Class II directors elected through the 2029 annual meeting, preserving board continuity.
Vera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Three Class II directors elected through the 2029 annual meeting, preserving board continuity
- James R. Meyers received 58,946,269 votes for, the strongest director support
- Michael M. Morrisey received 45,288,710 votes for and 13,814,671 withheld, signaling comparatively weaker support
- KPMG LLP appointment ratified for fiscal year ending December 31, 2026, with 61,834,842 votes for
- Executive compensation approved advisory-style, with 56,585,568 votes for versus 2,433,537 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vera Therapeutics, Inc. 8-K filings
Get the next VERA 8-K as it lands
Follow VERA for push alerts, or ask the research agent what this filing means.